New C-type hepatitis drug safe, no side effect, developer claims

MIP-11, an innovation Russian biotech company, has successfully completed the first stage of clinical trials of its new drug candidate to treat C-type hepatitis

MIP-11, an innovation Russian biotech company, has successfully completed the first stage of clinical trials of its new drug candidate to treat C-type hepatitis, being developed as part of its broader Aviron project, announced ChemRar, a biotech center just outside Moscow that is leading the research effort. MIP-11 has completed rigorous tests for safety and possible allergic side effects of its ABP-560, a brand new drug candidate that is believed to be able to block the C-type hepatitis virus? entry into healthy liver cells. A reported 30 healthy volunteers took part in the trials. They took the drug candidate once perorally, with doses varying for different groups from 50 to 150 milligrams. Under the Aviron project, the innovation company has plans to continue clinical trials next year to get further knowledge of the efficacy of the candidate...